Angiotensin II Type 1 Receptor Blockers
"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
Descriptor ID |
D047228
|
MeSH Number(s) |
D27.505.519.162.500
|
Concept/Terms |
Angiotensin II Type 1 Receptor Blockers- Angiotensin II Type 1 Receptor Blockers
- Type 1 Angiotensin Receptor Antagonists
- Type 1 Angiotensin Receptor Blockers
- Angiotensin II Type 1 Receptor Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".
This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in UAMS Profiles by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2020 | 0 | 1 | 1 | 2019 | 0 | 2 | 2 | 2018 | 1 | 1 | 2 | 2016 | 2 | 0 | 2 | 2015 | 1 | 0 | 1 | 2014 | 2 | 1 | 3 | 2012 | 1 | 2 | 3 | 2011 | 2 | 2 | 4 | 2010 | 2 | 2 | 4 | 2009 | 1 | 2 | 3 | 2008 | 1 | 0 | 1 | 2007 | 1 | 0 | 1 | 2006 | 1 | 0 | 1 | 2005 | 0 | 2 | 2 | 2004 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles over the past ten years.
-
Salah HM, Calcaterra G, Mehta JL. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):503-507.
-
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, S?nchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019 08 02; 20(1):292.
-
Fouda AY, Fagan SC, Ergul A. Brain Vasculature and Cognition. Arterioscler Thromb Vasc Biol. 2019 04; 39(4):593-602.
-
Sedl?kov? L, Kikerlov? S, Huskov? Z, Cervenkov? L, Ch?bov? VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kr?tk? V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5).
-
Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis. 2018 Aug; 12(8):217-231.
-
Fouda AY, Artham S, El-Remessy AB, Fagan SC. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence. Clin Sci (Lond). 2016 Feb; 130(4):221-38.
-
Fouda AY, Alhusban A, Ishrat T, Pillai B, Eldahshan W, Waller JL, Ergul A, Fagan SC. Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke. Mol Neurobiol. 2017 01; 54(1):661-670.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|